Story perspectives

Senator Hawley Slams FDA's Mifepristone Safety Study Delays

2/12/2026

Summary

Story summary

Senator Joshua Hawley (R-Mo.) met with FDA Commissioner Marty Makary to discuss the agency's safety study of mifepristone, expressing frustration.
Hawley said he was "really disappointed" by the lengthy timeline and called the process "a dead end."
He also criticized Makary's leadership, saying he is not serious about the issue.
The FDA plans to complete the study without compromising scientific integrity.
Hawley has pressed for action on mifepristone for months.

1 of 1

Story summary

Senator Joshua Hawley (R-Mo.) met with FDA Commissioner Marty Makary to discuss the agency's safety study of mifepristone, expressing frustration.
Hawley said he was "really disappointed" by the lengthy timeline and called the process "a dead end."
He also criticized Makary's leadership, saying he is not serious about the issue.
The FDA plans to complete the study without compromising scientific integrity.
Hawley has pressed for action on mifepristone for months.